Resources for HCPs to provide information on ophthalmology, with a particular focus on DMO.
THE ROLE OF LUCENTIS IN RESTARTING DMO AND WAMD CLINICS
In this video, Mr Mandeep Bindra explains the steps that the Medical Retina team undertook during the COVID-19 pandemic to ensure continuation of patient care. He also discusses plans to restart DMO clinics and shares advice on how to maintain social distancing and increase the efficiency of patient flow through the clinic.
RESTARTING DMO CLINICS
Professor Tunde Peto discusses how to approach restarting DMO clinics. She discusses the management, progression and assessment of diabetic patients.
AUDITING AND MANAGING DMO Q&A SESSION – LIVE WEBINAR, SEPTEMBER 2020
In this Q&A session from a live webinar in September 2020, Ms Bushra Mushtaq, Mr Ajay Bhatnagar and Mr Patrick Richardson answer questions about audit, managing DMO patients and running a medical retina service.
WOLVERHAMPTON EYE INFIRMARY AUDIT DATA
Mr Ajay Bhatnagar discusses his experience of using anti-VEGF injections for treating DMO at Wolverhampton Eye Infirmary. The audit covers all the patients who were treated over a period of 12 months.
ROYAL DERBY HOSPITAL AUDIT DATA
Mr Patrick Richardson from Royal Derby Hospital walks us through his DMO audit data. The audit was carried out between May 2013 and May 2016. These results were presented at the Nottingham Eye Symposium in January 2020.
LUCENTIS IN DMO
In this video, Mr Winfried Amoaku talks about the treatment of DMO, and in particular the efficacy of LUCENTIS in the treatment of DMO, presenting both real-world evidence and clinical trial data.
LUCENTIS 0.5 mg is indicated in adults for:
- The treatment of neovascular (wet) age-related macular degeneration (AMD)
- The treatment of visual impairment due to diabetic macular oedema (DMO)
- The treatment of proliferative diabetic retinopathy (PDR)
- The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)
- The treatment of visual impairment due to choroidal neovascularisation (CNV).
LUCENTIS 0.2 mg is indicated in preterm infants for:
- The treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.
DMO, diabetic macular oedema; HCP, healthcare professional; VEGF, vascular endothelial growth factor; wAMD, wet age-related macular degeneration.
- LUCENTIS® (ranibizumab) Summary of Product Characteristics, July 2020.